SomaLogic, Inc.

CM Life Sciences III Inc. (Nasdaq: CMII), sponsored by CM Life Sciences — an affiliate of Casdin Capital and Corvus Capital — completed its initial public offering in January 2021 with a focus on the life sciences sector. The blank-check company announced a definitive business combination with SomaLogic, Inc., a Boulder-based proteomics technology firm specializing in protein biomarker measurement platforms, shortly after its IPO. This 10-Q quarterly report, filed with the SEC on August 16, 2021, captures the company's financial position ahead of the merger closing in September 2021, after which the combined entity traded publicly under the SomaLogic name. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics on CMII and hundreds of other SPAC transactions.